|
1
|
Eichelberger L, Koch OM, Eble J, Ulbright
T, Juliar B and Cheng L: Maximum tumor diameter is an independent
predictor of prostate-specific antigen recurrence in prostate
cancer. Mod Pathol. 18:886–890. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Virolle T, Krones-Herzig A, Baron V,
Gregorio GG, Adamson ED and Mercola D: Egr-1 promotes growth and
survival of prostate cancer cells: identification of novel Egr-1
target genes. J Biol Chem. 278:11802–11810. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eid MA, Kumar MV, Iczkowski KA, Bostwick
DG and Tindall DJ: Expression of early growth response genes in
human prostate cancer. Cancer Res. 58:2461–2468. 1998.PubMed/NCBI
|
|
4
|
Scharnhorst V, Menke AL and Attema J:
EGR-1 enhances tumor growth and modulates the effect of the Wilms’
tumor 1 gene products on tumorigenicity. Oncogene. 19:791–800.
2000.PubMed/NCBI
|
|
5
|
Pignatelli M, Luna-Medina R, Perez-Rendon
A, Santos A and Perez-Castillo A: The transcription factor early
growth response factor-1 (EGR-1) promotes apoptosis of
neuroblastoma cells. Biochem J. 373:739–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Houston P, Campbell CJ, Svaren J,
Milbrandt J and Braddock M: The transcriptional corepressor NAB2
blocks Egr-1-mediated growth factor activation and agiogenesis.
Biochem Biophys Res Commun. 283:480–486. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adamson ED and Mercola D: Egr-1
transcription factor, multiple roles in prostate tumor cell growth
and survival. Tumour Biol. 23:93–102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banks MF, Gerasimovskaya EV, Tucker D,
Frid MG, Carpenter TC and Stenmark KR: Egr-1 antisense
oligonucleotides inhibit hypoxia-induced proliferation of pulmonary
artery adventitial fibroblast. J Appl Physiol. 98:732–738. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parra E, Ferreira J and Ortega A:
Overexpression of EGR-1 modulates the activity of NF-κB and AP-1 in
prostate carcinoma PC-3 and LNCaP cell lines. Int J Oncol.
39:345–352. 2011.PubMed/NCBI
|
|
10
|
Yang SZ and Abdulkadir S: Early growth
response gene 1 modulates androgen receptor signaling in prostate
carcinoma cells. J Biol Chem. 278:39906–39911. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu C, Yao J, Mercola D and Adamson E: The
transcription factor EGR-1 directly transactivates the fibronectin
gene and enhances attachment of human glioblastoma cell line U251.
J Biol Chem. 275:20315–20323. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krones-Herzig A, Mittal S, Yule K, Liang H
and English C: Early growth response 1 acts as a tumor suppressor
in vivo and in vitro via regulation of p53. Cancer Res.
65:5133–5141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sumathi P, Muthukkumar S, Han S, Sukhatme
V and Rangnekar V: Early growth response-1-dependent apoptosis is
mediated by p53. J Biol Chem. 272:20131–20138. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Virolle T, Adamson ED, Baron V, Birle D,
Mustelin T and de Belle I: The Egr-1 transcription factor directly
activates PTEN during irradiation-induced signalling. Nat
Cell Biol. 3:1124–1128. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parra E, Ortega A and Saenz L:
Downregulation of Egr-1 by siRNA inhibits growth of human prostate
carcinoma cell line PC-3. Oncol Rep. 22:1513–1518. 2009.PubMed/NCBI
|
|
16
|
Parra E, Ferreira J and Saenz L:
Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is
associated with decreased expression of AP-1 and NF-κB. Int J Mol
Med. 28:847–853. 2011.PubMed/NCBI
|
|
17
|
Parra E, Gutiérrez L and Ferreira J:
Increased expression of p21Waf1/Cip1 and JNK with
costimulation of prostate cancer cell activation by an siRNA Egr-1
inhibitor. Oncol Rep. 30:911–916. 2013.
|
|
18
|
Parra E, Ferreira J and Gutierrez L:
Decreased c-Abl activity in PC-3 and LNCaP prostate cancer cells
overexpressing the early growth response-1 protein. Oncol Rep.
31:422–427. 2014.PubMed/NCBI
|
|
19
|
Letterio JJ and Roberts AB: Regulation of
immune response by TGF-β. Annu Rev Immunol. 16:137–161. 1998.
|
|
20
|
Liu C, Yao J, de Belle I, Huang RP,
Adamson E and Mercola D: The transcription factor EGR-1 suppresses
transformation of human fibrosarcoma HT1080 cells by coordinated
induction of transforming growth factor-beta1, fibronectin, and
plasminogen activator inhibitor-1. J Biol Chem. 247:4400–4411.
1999. View Article : Google Scholar
|
|
21
|
Danielpour D, Dart LL, Flanders KC,
Roberts AB and Sporn MB: Immunodetection and quantitation of the
two forms of transforming growth factor-beta-1 and TGF-beta-2
secretion by cells in culture. J Cell Physiol. 138:79–86. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roberts AB and Sporn MB: Differential
expression of the TGF-β isoforms in embryogenesis suggests specific
roles in developing and adult tissue. Mol Reprod Dev. 32:91–98.
1992.
|
|
23
|
Millan FA, Denhez F, Kondaiah P and
Akhurst RJ: Embryonic gene expression patterns of TGF beta 1, beta
2 and beta 3 suggest different developmental functions in vivo.
Development. 111:131–143. 1991.PubMed/NCBI
|
|
24
|
Robert AB and Sporn MB: Physiological
actions and clinical applications of transforming growth factor-β
(TGF-β). Growth Factors. 8:1–9. 1993.
|
|
25
|
Liu Y, Liu H, Li J, Nadalin S,
Konigsrainer A, Weng H, Dooley S and Dijke P: Transforming growth
factor-β (TGF-β)-mediated connective tissue growth factor (CTGF)
expression in hepatic stellate cells requires Stat3 signaling
activation. J Biol Chem. 88:30708–30719. 2013.
|
|
26
|
Inoue K, Roussel MF and Sherr CJ:
Induction of ARF tumor suppressor gene expression and cell cycle
arrest by transcription factor DMP1. Proc Natl Acad Sci USA.
96:3993–3998. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mao L, Merlo A, Bedi G, Shapiro GI,
Edwards CD, Rollins BJ and Sidransky D: A novel p16INK4a transcrpt.
Cancer Res. 55:2995–2997. 1995.PubMed/NCBI
|
|
28
|
Kamijo T, Weber JD, Zambetti G, Zindy F,
Roussel MF and Sherr C: Functional and physical interactions of the
ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA.
95:8292–8297. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haupt Y, Maya R, Kazaz A and Oren M: Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kubbutat MH, Jones SN and Vousden KH:
Regulation of stability by mdms. Nature. 387:299–303. 1997.
View Article : Google Scholar
|
|
31
|
Woods YL, Xirodimas DP, Prescott AR,
Sparks A, Lane DP and Saville MK: p14 Arf promotes small
ubiquitin-like modifier conjugation of Werners helicase. J Biol
Chem. 279:50157–50166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu J, Zhang SS, Saito K, Williams K,
Arimura Y, Ma Y, Ke Y, Baron V, Mercola D, Feng GS, Adamson E and
Mustelin T: PTEN regulation by Akt-Egr-1-ARF-PTEN axis. EMBO J.
28:21–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Parra E: Inhibition of JNK-1 by small
interference RNA induces apoptotic signalling in PC-3 prostate
cancer cells. Int J Mol Med. 30:923–930. 2012.PubMed/NCBI
|
|
34
|
Parra E and Ferreira J: Modulation of the
proliferative response of prostate cancer cells to cisplatin
treatment by JNK-1/JNK-2 siRNA. Oncol Rep. 30:1936–1942. 2013.
|
|
35
|
Friedrich B, Janessa A, Artunc F,
Karl-Aicher W, Muller GA, Alexander D and Risler T: DOCA and TGF-β
induce early growth response gene-1 (Egr-1) expression. Cell
Physiol Biochem. 22:465–474. 2008.
|
|
36
|
Rodriguez-Barbero A, Obreo J, Alvarez P,
Pandiella A, Bernabeu C and Lopez-Novoa JM: Endoglin modulation of
TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK
activation. Cell Physiol Biochem. 18:135–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gitenay D and Baron VT: Is Egr-1 a
potential target for prostate cancer therapy? Future Oncol.
5:993–1003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kamijo T, Zindy F, Roussel MF, Quelle DE,
Downing JR, Ashmun RA, Grosveld G and Sherr CJ: Tumor suppression
at the mouse INK4a locus mediated by the alternative reading
frame product p19ARF. Cell. 91:649–659. 1997.
|
|
39
|
Sherr CJ and Weber JD: The ARF/p53
pathway. Curr Opin Genet Dev. 10:94–99. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haupt S, Berger M, Goldb Z and Haupt Y:
Apoptosis - the p53 network. J Cell Sci. 116:4077–4085. 2003.
View Article : Google Scholar : PubMed/NCBI
|
